Equity Profile

XENE

Xenon Pharmaceuticals Inc.

Health CareBiotechnology$6.2B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Xenon Pharmaceuticals Inc. is a biotechnology company focused on developing innovative therapies for neurological disorders....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors will closely analyze.

N/A

Revenue Growth

Investors will look for signs of revenue growth to gauge the success of Xenon's product pipeline and market acceptance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

XENE Q2-2026 Earnings Preview

Context

Company Snapshot

Xenon Pharmaceuticals Inc. is a biotechnology company focused on developing innovative therapies for neurological disorders. With a market cap of $6 billion, it operates in the health care sector, which is increasingly important as the demand for effective treatments grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+26.29%

Avg Stock Reaction

-0.39%

Last Quarter Recap

In the last quarter, Xenon reported an EPS of -$1.17, matching analyst expectations with a slight positive surprise. The stock reacted negatively, dropping 4.42% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Xenon's upcoming earnings are mixed, with no analyst estimates available. Investors are keen to see if the company can maintain its trend of beating EPS estimates.

Bull Case

If Xenon can report better-than-expected EPS and provide positive updates on clinical trials, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing news regarding its pipeline, the stock could face downward pressure.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for this quarter?

Given the company's history of EPS surprises, this figure will heavily influence investor sentiment and stock movement.

What updates will be provided on ongoing clinical trials?

The success or challenges faced in clinical trials can significantly affect the company's future prospects and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Xenon to surprise on the upside due to its strong history of beating EPS expectations.

Supporting Evidence

Xenon has a 75% EPS beat rate over the last eight quarters, indicating a strong potential for positive surprises.

The options market is pricing a 21.93% move, suggesting that investors are anticipating significant volatility, which could favor a positive outcome.

Key Risk

If the EPS comes in better than -$1.10, it could challenge the current cautious sentiment and shift the narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating the effectiveness of Xenon's product pipeline and its ability to deliver on financial expectations this quarter.

Bull Confirmed If

A reported EPS of better than -$1.10 would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS worse than -$1.30 would confirm the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±21.93%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a significant potential move in either direction, suggesting heightened uncertainty ahead of the earnings report.

Options are pricing ±21.9% while XENE has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

27.8%

Calls (40K)P/C Ratio: 0.50Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Xenon beats expectations, history suggests the stock could rise by around 2% on the first day, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance from management.

Miss

Should the company miss expectations, history suggests a potential decline of about 1.18% in the stock price.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of clinical trials for key products.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on any new partnerships or collaborations that could enhance product development.
4Insights into cost management strategies and their impact on future profitability.
5Any commentary on market trends and competitive landscape affecting the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Xenon Pharmaceuticals Inc. is a biotechnology company focused on developing innovative therapies for neurological disorders....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors will closely analyze.

N/A

Revenue Growth

Investors will look for signs of revenue growth to gauge the success of Xenon's product pipeline and market acceptance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

XENE Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+26.29%

Avg Stock Reaction

-0.39%

Last Quarter Recap

In the last quarter, Xenon reported an EPS of -$1.17, matching analyst expectations with a slight positive surprise. The stock reacted negatively, dropping 4.42% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Xenon's upcoming earnings are mixed, with no analyst estimates available. Investors are keen to see if the company can maintain its trend of beating EPS estimates.

Bull Case

If Xenon can report better-than-expected EPS and provide positive updates on clinical trials, it could lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing news regarding its pipeline, the stock could face downward pressure.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for this quarter?

Given the company's history of EPS surprises, this figure will heavily influence investor sentiment and stock movement.

What updates will be provided on ongoing clinical trials?

The success or challenges faced in clinical trials can significantly affect the company's future prospects and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Xenon to surprise on the upside due to its strong history of beating EPS expectations.

Supporting Evidence

Xenon has a 75% EPS beat rate over the last eight quarters, indicating a strong potential for positive surprises.

The options market is pricing a 21.93% move, suggesting that investors are anticipating significant volatility, which could favor a positive outcome.

Key Risk

If the EPS comes in better than -$1.10, it could challenge the current cautious sentiment and shift the narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating the effectiveness of Xenon's product pipeline and its ability to deliver on financial expectations this quarter.

Bull Confirmed If

A reported EPS of better than -$1.10 would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS worse than -$1.30 would confirm the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±21.93%

Historical Avg

±2.1%

Pricing rich

The options market is pricing in a significant potential move in either direction, suggesting heightened uncertainty ahead of the earnings report.

Options are pricing ±21.9% while XENE has averaged ±2.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

27.8%

Calls (40K)P/C Ratio: 0.50Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Xenon beats expectations, history suggests the stock could rise by around 2% on the first day, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further guidance from management.

Miss

Should the company miss expectations, history suggests a potential decline of about 1.18% in the stock price.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the progress of clinical trials for key products.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on any new partnerships or collaborations that could enhance product development.
4Insights into cost management strategies and their impact on future profitability.
5Any commentary on market trends and competitive landscape affecting the biotechnology sector.